U.S. markets open in 5 hours 38 minutes
  • S&P Futures

    3,914.00
    +10.25 (+0.26%)
     
  • Dow Futures

    31,524.00
    +103.00 (+0.33%)
     
  • Nasdaq Futures

    12,066.00
    +25.50 (+0.21%)
     
  • Russell 2000 Futures

    1,777.80
    +8.00 (+0.45%)
     
  • Crude Oil

    110.91
    +1.34 (+1.22%)
     
  • Gold

    1,827.60
    +2.80 (+0.15%)
     
  • Silver

    21.25
    +0.09 (+0.41%)
     
  • EUR/USD

    1.0595
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.15
    -0.08 (-0.29%)
     
  • GBP/USD

    1.2275
    +0.0005 (+0.04%)
     
  • USD/JPY

    135.6800
    +0.2340 (+0.17%)
     
  • BTC-USD

    20,860.12
    -471.09 (-2.21%)
     
  • CMC Crypto 200

    455.31
    -6.48 (-1.40%)
     
  • FTSE 100

    7,329.64
    +71.32 (+0.98%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Provention Bio Inc (NASDAQ: PRVB) revealed it had received a notification on April 2 from the FDA stating that the agency has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.

  • Notably, the FDA expressed concerns over teplizumab pharmacokinetics data and comparability when Lilly first put teplizumab into clinical trials.

  • Regulators assert the PK profiles from Provention’s studies and Lilly’s trials are not the same and asked for more data on April 2.

  • According to the regulators, such concerns mean that the candidate cannot start post-marketing and label discussions.

  • Investors responded sourly to the news after Thursday’s bell, with the stock crashing almost 40%.

  • Provention responded, noting it is “willing to discuss these issues.” Regulators had scheduled a May 27 AdCom to discuss the experimental drug, which will continue as planned.

  • The drug has a long history. In 2007, Eli Lilly And Co’s (NYSE: LLY) and MacroGenics Inc (NASDAQ: MGNX) partnered to develop and commercialize teplizumab.

  • In 2010, teplizumab failed a pivotal late-stage diabetes study undertaken by Eli Lilly, and it handed the rights back to MacroGenics.

  • In 2018, Provention Bio stepped in and in-licensed the drug from MacroGenics, hoping to bring the experimental drug back from the dead.

  • PRVB used teplizumab as their lead drug for a $56 million IPO filing.

  • Teplizumab is an investigational anti-CD3 monoclonal antibody for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals.

  • Price Action: PRVB shares plunged 40.7% at $5.77 in the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.